Receive the latest updates from Matrix Medical in real time to understand product information.
Recently, the company independently developed COLLEAL ® Vascular Closure Device has officially obtained registration approval from the National Medical Products Administration (NMPA), with registration certificate number 20253131504. This is the third Class III medical device registration certificate obtained by the company, and also the first product approved for listing in the company's puncture access management business. With the promotion of this product, the speed of industrialization of the company will be rapidly improved.
Product Name | Vascular Closure Device |
| Registration Certificate Number | NMPA20253131504 |
| Registration Category | Class III |
| Scope of Application | This product is suitable for patients undergoing femoral artery puncture to block and stop bleeding at the puncture site matched with 5F-8F sheath tube |
COLLSEAL ® Vascular Closure Device use of collagen material in hemostatic devices significantly improves the success rate and effectiveness of hemostasis, accurately filling the current demand gap in the field of puncture site hemostasis. Its advantages are as follows:
Material Innovation
Collagen comes into contact with blood, and platelets in the blood quickly adsorb onto collagen fibers to form fibrin, accelerating the formation of blood clots;
The natural fibrous structure of collagen provides a favorable environment for the repair of puncture sites; In most cases, collagen materials can be completely degraded within 28 days.
Realize precise occlusion of 8F large caliber extracorporeal vessels
Breaking through the limitations of traditional extracorporeal hemostatic instruments in controlling large caliber blood vessels, providing reliable options for complex clinical cases.
Balloon positioning
Visualize the precise location of the blockage.
The approval of the NMPA certificate this time is not only a recognition of the technical strength of the Matrix Medical R&D team, but also an important milestone for the company to move towards clinical applications and market expansion. Looking ahead to the future, Matrix Medical will take "innovation lights up life" as its mission, continue to cultivate clinical needs, use "Chinese original" to benefit global patients, and define the infinite possibilities of vascular intervention.
About Matrix
Future oriented innovation intervention technology platform
Hangzhou Matrix Medical Technology Co., Ltd. (hereinafter referred to as' Juzheng Medical ') was founded in 2021 and is the first high-tech enterprise in China to master intravascular photochemical cross-linking technology. It focuses on the research and development and production of innovative medical devices in the field of vascular intervention, and is committed to the research and development of a series of natural vascular stent products without implantation. Matrix Medical is headquartered in Hangzhou Future Science and Technology City and has a production base of 1700 square meters in Anji.
In the future, Matrix Medical will continue to adhere to the concept of "intervention without implantation", develop new interventional medical devices, take solving clinical pain points as the first starting point, truly provide new solutions for patients undergoing vascular intervention therapy, and actively promote the research and development of innovative technologies to further promote the development of the field of vascular intervention therapy.
